Amylin-based therapies
Amylin analogues and amylin-receptor agonists, such as cagrilintide, studied alone and in combination with GLP-1 therapies for weight management.
- Editorial attention
- Building
- Tracked this week
- 4
- Sources this week
- 3
- Last activity
- 1 day ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Amylin-based therapies at a glance
- About this topic
- Amylin analogues and amylin-receptor agonists, such as cagrilintide, studied alone and in combination with GLP-1 therapies for weight management.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Sep 29, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
What’s the latest on Amylin-based therapies?
0 totalNo briefings on this topic yet. Official records and trials below are updated continuously.
What do the official records show?
Primary sources and peer-reviewed research- New trial registered: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema. Investigational: trial-stage therapies are not approved for the use studied.
Which clinical trials are being tracked?
All trials- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk A/S. Conditions: Obesity. Investigational — not approved for the use studied.
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk A/S. Conditions: Obesity; Type 2 Diabetes. Investigational — not approved for the use studied.
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial (opens the source in a new tab)
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes (opens the source in a new tab)
- #EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's (opens the source in a new tab)